Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL

Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL

Multi-center retrospective analysis of patients with DLBCL aged ≥80 years old treated with R-CHOP-14 compared to other regimens. Patient data including baseline characteristics, histology, dose intensity and treatment outcomes will be extracted from hospital medical electronic records. Relative dose intensity (RDI) will be calculated as the percentage of the dose intensity achieved divided by the intended dose intensity. Primary endpoints are overall (OS), progression-free (PFS) and event-free survival (EFS), defined as time from diagnosis to death, death or progression/relapse, progression/relapse or treatment discontinuation.

Inclusion Criteria:

• histologically proven, untreated diffus large B-cell lymphoma (DLBCL)
• diagnosis between 2005 - 2019
• age ≥80 at diagnosis

Exclusion Criteria:

- diagnosis revision at a later timepoint